title: [Predictive value of molecular response after treatment with tyrosine kinase inhibitor for 3 months in patients with chronic myeloid leukemia].
abstract: OBJECTIVE
  To understand the predictive value of early monitoring BCR-ABL transcripts in patients with chronic myeloid leukemia (CML) after treatment with tyrosine kinase inhibitor (TKI), and to provides the information for early assessment of prognosis and treatment options.
  
  
  METHODS
  BCR-ABL transcripts of 53 CML patients before and after TKI treatment were detected by using real-time quantitative RT-PCR. The relationship between BCR-ABL transcripts level after TKI treatment for 3 months and the later molecular response, progression and mutation was analyzed.
  
  
  RESULTS
  The median values of BCR-ABL transcripts in peripheral blood samples from 30 newly diagnosed patients were 43.99%, which was used as a baseline of BCR-ABL transcripts for molecular response evaluation. Of 53 patients, 31 (58.49%) had a BCR-ABL mRNA ≤ 4.40% (reduced more than 1 log) and 22 (41.51%) greater than 4.40% (reduced to less than 1 log) after 3 months of TKI treatment. The former 31 patients had a significantly higher 18-months cumulative incidence of major molecular response (MMR) (90.32% vs 18.18%, P=0.000) and 3-year cumulative incidence of complete molecular response (CMR) (48.39% vs 0, P=0.000) compared with the latter 22 patients. The lower BCR-ABL level was, the earlier MMR reached. The proportion of patients with a mutation in group of BCR-ABL mRNA>4.40% was significantly higher than that of BCR-ABL mRNA ≤ 4.40% (22.73% vs 0, P=0.021). The incidence of progression increased in group of BCR-ABL mRNA>4.40%, but the difference was not statistically significant (P=0.052).
  
  
  CONCLUSIONS
  It is important for the prognosis evaluation of the patients to monitor the level of BCR-ABL transcripts at 3 months after TKI treatment, which might help to early optimization of treatment and to improve curative effect of CML patients.
authors.affiliation: Department of Hematology, Guangdong General Hospital/Guang-dong Academy of Medical Sciences, Guangzhou 510080, China.
authors.forename: Su-xia
authors.initials: SX
authors.lastname: Geng
authors.forename: Jian-yu
authors.initials: JY
authors.lastname: Weng
authors.forename: Xin
authors.initials: X
authors.lastname: Huang
authors.forename: Ze-sheng
authors.initials: ZS
authors.lastname: Lu
authors.forename: Ping
authors.initials: P
authors.lastname: Wu
authors.forename: Li-si
authors.initials: LS
authors.lastname: Huang
authors.forename: Long
authors.initials: L
authors.lastname: Liu
authors.forename: Xin
authors.initials: X
authors.lastname: Du
mesh_terms: D000328:Adult; D000368:Aged; D005260:Female; D016044:Fusion Proteins, bcr-abl / Q000097:blood; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000175:diagnosis / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011237:Predictive Value of Tests; D011379:Prognosis; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D012333:RNA, Messenger / Q000235:genetics; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D047428:Protein Kinase Inhibitors; D012333:RNA, Messenger; D016044:Fusion Proteins, bcr-abl